VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2018 | E-selectin antagonist uproleselan for R/R AML: efficacy and safety data

Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy and safety results for the E-selectin antagonist uproleselan, in addition to chemotherapy, for relapsed/refractory acute myeloid leukemia (NCT03616470). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter